Shares of Aegerion Pharmaceuticals opened at 36.12 on Tuesday. Aegerion Pharmaceuticals has a 52 week low of $11.75 and a 52 week high of $37.10. The stock’s 50-day moving average is currently $28.72. The company’s market cap is $920.2 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday. They set a buy rating and a $39.00 price target on the stock. Separately, analysts at Lazard Capital Markets upgraded shares of Aegerion Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Monday, February 11th. Finally, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $37.00 in a research note to investors on Monday, January 28th. They now have a buy rating on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.